The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+

Drug regulator asks Serum Institute to submit more information on Oxford Covid-19 vaccine

Drug regulator asks Serum Institute to submit more information on Oxford Covid-19 vaccine
Drug regulator asks Serum Institute to submit more information on Oxford Covid-19 vaccine
The SII has already begun manufacturing the vaccine.

Synopsis

The Pune-based company is conducting phase-3 trials of the Oxford Covid-19 vaccine in India as part of international trials.

NEW DELHI: India’s drug regulatory authority has sought more information from the Serum Institute of India (SII) on its potential Covid-19 vaccine, Covishield, as the company has yet to submit important documents. The Pune-based company is conducting phase-3 trials of the Oxford Covid-19 vaccine in India as part of international trials.The office of the drug regulator has asked the SII to submit a manufacturing process development report of
Share This Article
  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • COMMENT

To Read the Full Story, Become an ET Prime Member

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Access the exclusive Economic Times stories, Editorial and Expert opinion

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads
  • Comment & Engage with ET Prime community
  • Exclusive invites to Virtual Events with Industry Leaders
  • A trusted team of Journalists & Analysts who can best filter signal from noise
The Economic Times